BACE1 and Alzheimer disease: Another picolinamide-based (Fig. 16) oral BACE-1 inhibitor is verubecestat (MK8931), which has been reported to reduce Aβ levels in AD patients.158,159 Nevertheless, in clinical trials, it caused no improvement in cognitive function in mild to moderate AD patients.158 Furthermore, some studies reported a greater decline in cognitive functions among patients receiving verubecestat than those receiving placebo.160